Suprastat is a novel, potent and selective HDAC6 (Histone Deacetylase 6) inhibitor with the ability to potentiate immunotherapy in melanoma. In vitro characterization of Suprastat demonstrates subnanomolar HDAC6 inhibitory potency and a hundred- to a thousand-fold HDAC6 selectivity over the other HDAC isoforms. In vivo studies reveal that a combination of Suprastat and anti-PD1 immunotherapy […]

Tinostamustine (also known as EDO-S101; EDO-S 101; Minomustine) is a novel, potent, fisrt-in-class alkylating agent and pan histone-deacetylase (HDAC) inhibitor with anticancer activity.

WT-161 (WT161) is a potent, selective and orally bioavailable HDAC6 inhibitor with IC50 value of 0.40 nM.

Apicidin (OSI-2040; OSI2040) is a novel and potent histone deacetylases (HDAC) inhibitor and apoptosis inducer with potential anticancer activity.

HDAC8-IN-1 is a novel and potent HDAC8 inhibitor with an IC50 of 27.2 nM.

UF010 (UF-010; UF 010) is a novel, potent and selective class I HDAC inhibitor with potential anticancer activities.

Remetinostat (formerly known as SHP-141) is an inhibitor of histone deacetylase (HDAC) developed by Medivir as a topical application for use in early stage CTCL (Cutaneous T-cell lymphoma).

TH34 is a novel, potent and selective HDAC6/8/10 (histone deacetylase) inhibitor for neuroblastoma therapy.

BRD6688 (BRD-6688; BRD 6688) is a novel and potent HDAC1/2/3 inhibitor with IC50s of 21 nM, 100 nM, and 11.48 μM, respectively.

Pivanex (AN-9; AN 9; AN9; pivaloyloxymethyl butyrate; Titan) is a novel and potent histone deacetylase/HDAC inhibitor with anticancer and antiangiogenic properties.